Search Results - "Von Roemeling, Christina A"

Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity by von Roemeling, Christina A., Wang, Yifan, Qie, Yaqing, Yuan, Hengfeng, Zhao, Hai, Liu, Xiujie, Yang, Zhaogang, Yang, Mingming, Deng, Weiye, Bruno, Katelyn A., Chan, Charles K., Lee, Andrew S., Rosenfeld, Stephen S., Yun, Kyuson, Johnson, Aaron J., Mitchell, Duane A., Jiang, Wen, Kim, Betty Y. S.

“…Tumour cell phagocytosis by antigen presenting cells (APCs) is critical to the generation of antitumour immunity. However, cancer cells can evade phagocytosis…”
Get full text

Pathway signature and cellular differentiation in clear cell renal cell carcinoma by Tun, Han W, Marlow, Laura A, von Roemeling, Christina A, Cooper, Simon J, Kreinest, Pamela, Wu, Kevin, Luxon, Bruce A, Sinha, Mala, Anastasiadis, Panos Z, Copland, John A

“…Clear cell renal cell carcinoma (ccRCC) is the most common kidney cancer. The purpose of this study is to define a biological pathway signature and a cellular…”
Get full text

Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy by Yuan, Hengfeng, Jiang, Wen, von Roemeling, Christina A., Qie, Yaqing, Liu, Xiujie, Chen, Yuanxin, Wang, Yifan, Wharen, Robert E., Yun, Kyuson, Bu, Guojun, Knutson, Keith L., Kim, Betty Y. S.

“…A multivalent bi-specific nanoconjugate can promote immune cells to recognize and eradicate cancer cells in a receptor targeted manner, leading to the…”
Get full text

Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes by Qie, Yaqing, Yuan, Hengfeng, von Roemeling, Christina A., Chen, Yuanxin, Liu, Xiujie, Shih, Kevin D., Knight, Joshua A., Tun, Han W., Wharen, Robert E., Jiang, Wen, Kim, Betty Y.S.

“…Nanomedicine is a burgeoning industry but an understanding of the interaction of nanomaterials with the immune system is critical for clinical translation…”
Get full text

Aberrant Lipid Metabolism in Anaplastic Thyroid Carcinoma Reveals Stearoyl CoA Desaturase 1 as a Novel Therapeutic Target by von Roemeling, Christina A, Marlow, Laura A, Pinkerton, Anthony B, Crist, Angela, Miller, James, Tun, Han W, Smallridge, Robert C, Copland, John A

“…Context: Currently there are no efficacious therapies for patients with anaplastic thyroid carcinoma (ATC) that result in long-term disease stabilization or…”
Get full text

Neuronal Pentraxin 2 Supports Clear Cell Renal Cell Carcinoma by Activating the AMPA-Selective Glutamate Receptor-4 by VON ROEMELING, Christina A, RADISKY, Derek C, MARLOW, Laura A, COOPER, Simon J, GREBE, Stefan K, ANASTASIADIS, Panagiotis Z, TUN, Han W, COPLAND, John A

“…Clear cell renal cell carcinoma (ccRCC) is the most common subtype of kidney cancer and has the highest propensity to manifest as metastatic disease. Recent…”
Get full text

Stearoyl-CoA Desaturase 1 Is a Novel Molecular Therapeutic Target for Clear Cell Renal Cell Carcinoma by VON ROEMELING, Christina A, MARLOW, Laura A, WEI, Johnny J, COOPER, Simon J, CAULFIELD, Thomas R, KEVIN WU, TAN, Winston W, TUN, Han W, COPLAND, John A

“…We set out to identify Stearoyl-CoA desaturase 1 (SCD1) as a novel molecular target in clear cell renal cell carcinoma (ccRCC) and examine its role in tumor…”
Get full text

Adeno-associated virus delivered CXCL9 sensitizes glioblastoma to anti-PD-1 immune checkpoint blockade by von Roemeling, Christina A., Patel, Jeet A., Carpenter, Savannah L., Yegorov, Oleg, Yang, Changlin, Bhatia, Alisha, Doonan, Bently P., Russell, Rylynn, Trivedi, Vrunda S., Klippel, Kelena, Ryu, Daniel H., Grippin, Adam, Futch, Hunter S., Ran, Yong, Hoang-Minh, Lan B., Weidert, Frances L., Golde, Todd E., Mitchell, Duane A.

“…There are numerous mechanisms by which glioblastoma cells evade immunological detection, underscoring the need for strategic combinatorial treatments to…”
Get full text

Reexpression of tumor suppressor, sFRP1, leads to antitumor synergy of combined HDAC and methyltransferase inhibitors in chemoresistant cancers by Cooper, Simon J, von Roemeling, Christina A, Kang, Kylie H, Marlow, Laura A, Grebe, Stefan K, Menefee, Michael E, Tun, Han W, Colon-Otero, Gerardo, Perez, Edith A, Copland, John A

“…Metastatic solid tumors are aggressive and mostly drug resistant, leading to few treatment options and poor prognosis as seen with clear cell renal cell…”
Get full text

Designing nanomedicine for immuno-oncology by Jiang, Wen, von Roemeling, Christina A., Chen, Yuanxin, Qie, Yaqing, Liu, Xiujie, Chen, Jianzhu, Kim, Betty Y. S.

“…Two major obstacles facing cancer nanomedicine are the tendency of nanoparticles to be taken up by normal tissues and organs and the nanoparticles' inability…”
Get full text

Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle Delivery by Chen, Yuanxin, Liu, Xiujie, Yuan, Hengfeng, Yang, Zhaogang, von Roemeling, Christina A., Qie, Yaqing, Zhao, Hai, Wang, Yifan, Jiang, Wen, Kim, Betty Y. S.

“…A major challenge in the development of cancer nanomedicine is the inability for nanomaterials to efficiently penetrate and deliver therapeutic agents into…”
Get full text

Oral IRAK-4 Inhibitor CA-4948 Is Blood-Brain Barrier Penetrant and Has Single-Agent Activity against CNS Lymphoma and Melanoma Brain Metastases by Von Roemeling, Christina A, Doonan, Bently P, Klippel, Kelena, Schultz, Daniel, Hoang-Minh, Lan, Trivedi, Vrunda, Li, Chenglong, Russell, Rylynn A, Kanumuri, Raju S, Sharma, Abhisheak, Tun, Han W, Mitchell, Duane A

“…An ongoing challenge in cancer is the management of primary and metastatic brain malignancies. This is partly due to restrictions of the blood-brain barrier…”
Get full text

Lessons from immuno-oncology: a new era for cancer nanomedicine? by Jiang, Wen, Yuan, Hengfeng, Chan, Charles K., von Roemeling, Christina A., Yan, Zuoqin, Weissman, Irving L., Kim, Betty Y. S.

“…Despite a decade of intensive preclinical research, the translation of cancer nanomedicine to the clinic has been slow. Here, we discuss how recent lessons…”
Get full text

Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions by Bastea, Ligia I, Liou, Geou-Yarh, Pandey, Veethika, Fleming, Alicia K, von Roemeling, Christina A, Doeppler, Heike, Li, Zhimin, Qiu, Yushi, Edenfield, Brandy, Copland, John A, Tun, Han W, Storz, Peter

“…During development of pancreatic cancer, alternatively activated macrophages contribute to fibrogenesis, pancreatic intraepithelial neoplasia (PanIN) lesion…”
Get full text

Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration by von Roemeling, Christina A., Marlow, Laura A., Radisky, Derek C., Rohl, Austin, Larsen, Hege E., Wei, Johnny, Sasinowska, Heather, Zhu, Heng, Drake, Richard, Sasinowski, Maciek, Tun, Han W., Copland, John A.

Get full text

Targeting lipid metabolism for the treatment of anaplastic thyroid carcinoma by von Roemeling, Christina A, Copland, John A

“…Anaplastic thyroid carcinoma (ATC) is the rarest subtype of thyroid cancer; however, it disproportionately accounts for a large percentage of all thyroid…”
Get more information

Accelerated bottom-up drug design platform enables the discovery of novel stearoyl-CoA desaturase 1 inhibitors for cancer therapy by von Roemeling, Christina A, Caulfield, Thomas R, Marlow, Laura, Bok, Ilah, Wen, Jiang, Miller, James L, Hughes, Robert, Hazlehurst, Lori, Pinkerton, Anthony B, Radisky, Derek C, Tun, Han W, Kim, Yon Son Betty, Lane, Amy L, Copland, John A

“…Here we present an innovative computational-based drug discovery strategy, coupled with machine-based learning and functional assessment, for the rational…”
Get full text

Osteopontin is a multi-faceted pro-tumorigenic driver for central nervous system lymphoma by Yushi, Qiu, Li, Zhimin, Von Roemeling, Christina A, Doeppler, Heike, Marlow, Laura A, Kim, Betty Y S, Radisky, Derek C, Storz, Peter, Copland, John A, Tun, Han W

“…Osteopontin (OPN) is the most upregulated gene in primary central nervous system lymphoma (PCNSL) compared to non-CNS diffuse large B cell lymphoma (DLBCL). We…”
Get full text

Foxo3a drives proliferation in anaplastic thyroid carcinoma through transcriptional regulation of cyclin A1: a paradigm shift that impacts current therapeutic strategies by Marlow, Laura A, von Roemeling, Christina A, Cooper, Simon J, Zhang, Yilin, Rohl, Stephen D, Arora, Shilpi, Gonzales, Irma M, Azorsa, David O, Reddi, Honey V, Tun, Han W, Döppler, Heike R, Storz, Peter, Smallridge, Robert C, Copland, John A

“…The Forkhead transcription factor, FoxO3a, is a known suppressor of primary tumor growth through transcriptional regulation of key genes regulating cell cycle…”
Get full text

Correction: Corrigendum: Surface modification of nanoparticles enables selective evasion of phagocytic clearance by distinct macrophage phenotypes by Qie, Yaqing, Yuan, Hengfeng, von Roemeling, Christina A., Chen, Yuanxin, Liu, Xiujie, Shih, Kevin D., Knight, Joshua A., Tun, Han W., Wharen, Robert E., Jiang, Wen, Kim, Betty Y. S.

“…Scientific Reports 6: Article number: 26269; published online: 19 May 2016; updated: 01 August 2016 In this Article, Wen Jiang is incorrectly affiliated with:…”
Get full text